Septerna, Inc. (SEPN) stock
SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30176% above fair value
$41.67−0.93 (-2.18%)
Close on Nov 16, 2026Market cap $1.95BP/E –Yield –
Septerna r&d expenses
Research and development expenses are spending on new products and technology.
Septerna's R&D Expenses for the twelve months ending Sep 30, 2026 was $133.08M, up 56.5% year over year. For fiscal 2025 it was $97.58M, up 49.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.58M | +49.4% |
| FY2024 | Dec 31, 2024 | $65.34M | +81.6% |
| FY2023 | Dec 31, 2023 | $35.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $36.56M | +50.7% |
| Q2 FY2026 | Jun 30, 2026 | $35.13M | +58.3% |
| Q1 FY2026 | Mar 31, 2026 | $29.54M | +53.3% |
| Q4 FY2025 | Dec 31, 2025 | $31.86M | +64.9% |
| Q3 FY2025 | Sep 30, 2025 | $24.26M | +36.1% |
| Q2 FY2025 | Jun 30, 2025 | $22.19M | +47.6% |
| Q1 FY2025 | Mar 31, 2025 | $19.27M | +46.5% |
| Q4 FY2024 | Dec 31, 2024 | $19.32M | +87.1% |
| Q3 FY2024 | Sep 30, 2024 | $17.83M | +92.1% |
| Q2 FY2024 | Jun 30, 2024 | $15.04M | – |
| Q1 FY2024 | Mar 31, 2024 | $13.15M | – |
| Q4 FY2023 | Dec 31, 2023 | $10.33M | – |
| Q3 FY2023 | Sep 30, 2023 | $9.28M | – |
See a number that looks wrong?